These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 12780666)
1. The first report from the patient outcomes registry for transplant effects on life (PORTEL): differences in side-effects and quality of life by organ type, time since transplant and immunosuppressive regimens. Hathaway D; Winsett R; Prendergast M; Subaiya I Clin Transplant; 2003 Jun; 17(3):183-94. PubMed ID: 12780666 [TBL] [Abstract][Full Text] [Related]
2. Quality of life in kidney recipients: comparison of tacrolimus and cyclosporine-microemulsion. Reimer J; Franke GH; Philipp T; Heemann U Clin Transplant; 2002 Feb; 16(1):48-54. PubMed ID: 11982615 [TBL] [Abstract][Full Text] [Related]
3. A quality of life comparison in cyclosporine- and tacrolimus-treated renal transplant recipients across Canada. Prasad GV; Nash MM; Keough-Ryan T; Shapiro RJ J Nephrol; 2010; 23(3):274-81. PubMed ID: 20383867 [TBL] [Abstract][Full Text] [Related]
4. A numerical scale comparison of renal transplant recipient experience with and opinions about calcineurin inhibitors. Prasad GV; Nash MM; McFarlane PA; Zaltzman JS Nephron Clin Pract; 2004; 97(2):c35-40. PubMed ID: 15218328 [TBL] [Abstract][Full Text] [Related]
5. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. Taylor DO; Barr ML; Radovancevic B; Renlund DG; Mentzer RM; Smart FW; Tolman DE; Frazier OH; Young JB; VanVeldhuisen P J Heart Lung Transplant; 1999 Apr; 18(4):336-45. PubMed ID: 10226898 [TBL] [Abstract][Full Text] [Related]
6. Immunosuppressant side effect profile does not differ between organ transplant types. Winsett RP; Stratta RJ; Alloway R; Wicks MN; Hathaway DK Clin Transplant; 2001; 15 Suppl 6():46-50. PubMed ID: 11903386 [TBL] [Abstract][Full Text] [Related]
7. Quality of life of older patients undergoing renal transplantation: finding the right immunosuppressive treatment. Perlman RL; Rao PS Drugs Aging; 2014 Feb; 31(2):103-9. PubMed ID: 24399579 [TBL] [Abstract][Full Text] [Related]
8. Switching from cyclosporine to tacrolimus leads to improved disease-specific quality of life in patients after kidney transplantation. Franke GH; Trampenau C; Reimer J; Transplant Proc; 2006 Jun; 38(5):1293-4. PubMed ID: 16797285 [TBL] [Abstract][Full Text] [Related]
9. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Armenti VT; Radomski JS; Moritz MJ; Gaughan WJ; Philips LZ; McGrory CH; Coscia LA; Clin Transpl; 2002; ():121-30. PubMed ID: 12971441 [TBL] [Abstract][Full Text] [Related]
10. Immune monitoring with a lymphocyte adenosine triphosphate assay in kidney transplant recipients treated with a calcineurin inhibitor. Sugiyama K; Tsukaguchi M; Toyama A; Satoh H; Saito K; Nakagawa Y; Takahashi K; Tanaka S; Onda K; Hirano T Exp Clin Transplant; 2014 Jun; 12(3):195-9. PubMed ID: 24907718 [TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life after different types of solid organ transplantation. Pinson CW; Feurer ID; Payne JL; Wise PE; Shockley S; Speroff T Ann Surg; 2000 Oct; 232(4):597-607. PubMed ID: 10998658 [TBL] [Abstract][Full Text] [Related]
12. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group. Gruessner RW Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719 [TBL] [Abstract][Full Text] [Related]
14. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity. Tönshoff B; Höcker B Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497 [TBL] [Abstract][Full Text] [Related]
15. [Quality of life following transplantation. The impact ofa new immunosuppressive substance]. Lütkes P; Franke G; Witzke O; Zimmermann U; Kohnle M; Philipp T; Heemann U Zentralbl Chir; 1999; 124(2):90-4. PubMed ID: 10209841 [TBL] [Abstract][Full Text] [Related]
16. New strategies using 'low-dose' mycophenolate mofetil to reduce acute rejection in patients following kidney transplantation. Ulsh PJ; Yang HC; Holman MJ; Ahsan N J Transpl Coord; 1999 Jun; 9(2):114-8. PubMed ID: 10703393 [TBL] [Abstract][Full Text] [Related]
17. Assessment of health-related quality-of-life in patients after heart transplantation under therapy with tacrolimus or cyclosporine. von Steinbüchel N; Limm H; Leopold C; Carr D Transpl Int; 2000; 13 Suppl 1():S609-14. PubMed ID: 11112084 [TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life outcomes after kidney transplantation. Fiebiger W; Mitterbauer C; Oberbauer R Health Qual Life Outcomes; 2004 Jan; 2():2. PubMed ID: 14713316 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results. Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M; Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208 [TBL] [Abstract][Full Text] [Related]
20. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients. Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]